High-Dose Cholinergic Therapy With Rivastigmine Patch Does Not Prolong QTc Time in Patients With Alzheimer’s Disease
J Clin Psychiatry 2014;75(3):288 [letter]
© Copyright 2014 Physicians Postgraduate Press, Inc.
Access to this article is available to valid users
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Register: If you do not have one already, register for a free account.
Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.
Cholinesterase inhibitors are widely accepted as established therapeutic intervention across the entire severity spectrum of Alzheimer’s disease. However, fear of increased corrected QT interval (QTc) time is one of the main reasons for nonprescription of cholinergic drugs. While it is generally accepted that therapeutic efficacy of cholinergic therapy is dose dependent, a large number of patients are treated with a low dose for fear of dose-dependent increase of QTc time.